Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.
Drayman N, Jones KA, Azizi SA, Froggatt HM, Tan K, Maltseva NI, Chen S, Nicolaescu V, Dvorkin S, Furlong K, Kathayat RS, Firpo MR, Mastrodomenico V, Bruce EA, Schmidt MM, Jedrzejczak R, Muñoz-Alía MÁ, Schuster B, Nair V, Botten JW, Brooke CB, Baker SC, Mounce BC, Heaton NS, Dickinson BC, Jaochimiak A, Randall G, Tay S.
Drayman N, et al. Among authors: bruce ea.
bioRxiv [Preprint]. 2020 Sep 1:2020.08.31.274639. doi: 10.1101/2020.08.31.274639.
bioRxiv. 2020.
PMID: 32908976
Free PMC article.
Updated.
Preprint.